ArticleLeukemia2016
New drug approvals in acute myeloid leukemia: what's the best end point?
Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Anticancer effects of disulfiram: a systematic review of in vitro, animal, and human studies.Systematic reviews · 2022Pooled it
- Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614).Blood advances · 2019Trial
- Article
- Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial.HemaSphere · 2021Article
- Article
- Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful Benefits.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Clinical value of event-free survival in acute myeloid leukemia.Blood advances · 2020Article
- Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?Leukemia · 2020Review
- Single-agent and combination biologics in acute myeloid leukemia.Hematology. American Society of Hematology. Education Program · 2019Review
- Article
- Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come.Haematologica · 2019Article
- Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development.Current medical research and opinion · 2018Article
- New drugs in AML: uses and abuses.Leukemia · 2018Article
- Review
- Leukemic stem cells: identification and clinical application.International journal of hematology · 2017Review
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Blood · 2017Review
- Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials.Journal of Cancer · 2017Article
- Acute Myeloid Leukemia: How Do We Measure Success?Current hematologic malignancy reports · 2016Review
- Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology.Journal of the advanced practitioner in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.